Clinical trial · Interventional
Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Treatment-Related | Malignant Neoplasm | ALIAS | 0.85 |
| Smoking Cessation | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupropion | Drug | — | UNRESOLVED |
| High-intensity counseling | Behavioral | — | UNRESOLVED |
| Long-acting nicotine replacement therapy | Drug | — | UNRESOLVED |
| Low-intensity counseling | Behavioral | — | UNRESOLVED |
| Nicotine Replacement Products | Drug | — | UNRESOLVED |
| No nicotine replacement therapy | Other | — | UNRESOLVED |
| Varenicline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (12)
- type
- EXPERIMENTAL
- label
- Group 1: Varenicline, Intense Counselling and NRT
- description
- Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
- interventionNames
- Drug: Varenicline
- Behavioral: High-intensity counseling
- Drug: Nicotine Replacement Products
- type
- EXPERIMENTAL
- label
- Group : Varenicline, Intense Counselling
- description
- Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
- interventionNames
- Drug: Varenicline
- Behavioral: High-intensity counseling
- Other: No nicotine replacement therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * newly diagnosed or recurrent tobacco related malignancy * smoked at least 1 cigarette within 4 weeks of study enrollment * 10-pack year history of cigarette smoking * smoked at least 1 cigarette within 1 month of cancer diagnosis * life expectancy greater than 1 year Exclusion Criteria: * allergy to buproprion, varenicline and transdermal medicine * history of suicide attempt * hospitalized for psychiatric illness within past 2 years * history of active or uncontrolled eating disorder * uncontrolled epilepsy or seizure disorder * pregnant or lactating * within 3 months of myocardial infarction * unstable angina * uncontrolled hypertension * serious arrhythmia * history of taking varenicline or buproprion within one month of enrollment * concurrent enrollment in tobacco cessation therapy
References
Publications (0)
Data not yet available